Comparison of the Efficacy of Topical 0.2% Loteprednol Etabonate and Topical 0.1% Dexamethasone in Impending Recurrent Pterygium.
Article Sidebar
Main Article Content
Abstract
Background: Recurrence is a common complication of pterygium excision. This study has objective too evaluate the efficacy of topical 0.2% loteprednol etabonate, a ‘soft steroid’, compared to topical 0.1% dexamethasone widely used in postoperative pterygium excision to prevent the recurrence of pterygium.
Methods: Randomized control trial study, patients undergoing pterygium excision with amniotic membrane transplantation who developed impending recurrent pterygium stage 3 were randomized into 2 groups. Group 1 received 0.2% loteprednol etabonate and group 2 received 0.1% dexamethasone. The rate of true recurrence of pterygium, impending recurrent pterygium scores, and intraocular pressure were compared between the groups.
Results: Fifty-four eyes of 54 patients in each group were included. The true recurrence of pterygium in between groups was not significantly different (15 patients [27.8%] in group 1 vs. 17 patients [31.5%] in group 2, p = 0.67). However, the time to recurrence ± SD was longer in group 2 than in group 1 (3.35 ± 1.7 vs. 1.47 ± 0.8 months, respectively, p = 0.0002). Scores of impending recurrent pterygium at 1 month and 6 months were not significantly different between both groups (p =0.26 and p = 0.1, respectively), but were significantly higher in group 2 at 3 months (p = 0.015). No ocular hypertension was found in group 1, but found 6 patients (11.1%) in group 2.
Conclusions: This study found the efficacy of 0.2% loteprednol etabonate was non-inferior to 0.1% dexamethasone in preventing the recurrence of pterygium and controlling inflammation after pterygium excision with more safety to avoid steroid-induced ocular hypertension.
Article Details
References
2) Sherwin JC, Hewitt AW, Kearns LS, Griffiths LR, Mackey DA, Coroneo MT. The association between pterygium and conjunctival ultraviolet autofluorescence: The Norfolk Island Eye Study. Acta Ophthalmologica 2013;91(4):363-70.
3) Yaisawang S, Piyapattanakorn P. Role of post-operative topical corticosteroids in recurrence rate after pterygium excision with conjunctival autograft. J Med Assoc Thai 2003;86 (Supp 2):S215-223.
4) Hirst LW. The treatment of pterygium. Surv Ophthalmol 2003;48:145-180. 2.
5) Kucukerdonmez C, Akova YA, Altinors DD. Comparison of conjunctival autograft with amniotic membrane transplantation for pterygium surgery:surgical and cosmetic outcome. Cornea 2007;26:407-413.
6) Pikkel J, Porges Y, Ophir A. Halting pterygium recurrence by postoperative 5-fluorouracil. Cornea 2001;20(2):168-171.
7) Sheha H, Liu J, Tseng SCG. Inflammation and the recurrence of pterygium. Advance ocular care 2010;49-51.
8) Basic and clinical science course. Fundamentals and principles of ophthalmology. Section 2. American academy of ophthalmology 2014-2015:329-334.
9) Anguria P, Ntuli S, Carmichael T. Young patient’s age determines ptetrygium recurrence after surgery. Afr Health Sci 2014 Mar; 14(1):72-76.
10) Han SB, Jeon HS, Kim M, Lee SJ. Risk factors for recurrence after pterygium surgery: an image analysis study. Cornea 2016 Aug;35(8):1097-103.
11) Sang WH, Joon HP, Hong KK. Clinical analysis of risk factors contribution to recurrence of pterygium after excision and graft surgery. Int J Ophthalmol 2015;8(3):522-527.
12) Olusany BA, Ogun OA, Bekibele CO, Ashaye AO. Risk factors for pterygium recurrence after surgical excision with combined conjunctival autograft (CAG) and intraoperative antimetabolite use. Afr J Med Sci 2014 Mar;43(1):35-40.
13) Pi SM, Nabeel M. Pterygium recurrence related to its size and corneal involvement. JCPSP 2013;23(2):120-123.
14) Dan Y, Olivia LL. Risk factors for pterygium recurrence after primary excision. IOVS 2011 Apr;52(14).
15) Raffaele N, Federico T. How to minimize pterygium recurrence rates: clinical perspectives. Clin Ophthalmol 2018;12:2347-2362.
16) Kim KW, Kim JC. Current approaches and future directions in the management of pterygium. Int J Ophthalmol 2018;11(5):709-711.
17) Hosam S, Jingbo L, Scheffer T. Inflammation and the recurrence of pterygium. Advance Ocular Care.2010 Jan.
18) Prabhasawat P, Tesavibul N, Leelapatranura K, Phonjan T. Efficacy of subconjunctival 5-fluorouracil and triamcinolone injection in impending recurrent pterygium. Ophthalmology 2006;113:1102-1109.
19) Armaly MF. Effect of corticosteroid on intraocular pressure and fluid dynamics (II). The effect of dexamethasone in the glaucomatous eye. Arch Ophthalmol 1963;70:492.
20) Makornwattana M, Suphachearaphan W. Incidence of steroid induced-ocular hypertension in postoperative ptergum excision. J Med Assoc Thai 2015;98(Suppl 2):S151-S157.
21) Bodor N, Buchwald P. Soft drug design: general principles and recent applications. Med Res Rev 2000;20(1):58–101.
22) Timothy LC, John DS. Loteprednol etabonate for inflammatory conditions of the anterior segment of the eye: twenty years of clinical experience with a retrometabolically designed corticosteroid. Expert Opin Pharmacother 2018;19(4):337-353.
23) John DS, Timothy LC, Megan EC. Impact of the topical ophthalmic corticosteroid loteprednol etabonate on intraocular pressure. Adv Ther 2016;33:532-552.